Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Diamond Equity Research Update 5 September 2024

Friday, September 6, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has made significant progress in its clinical studies, including the initiation of a Phase 1/2a study for Betabart (RV-01). The company has also received IND approval from the US FDA, allowing them to advance their therapeutic study targeting B7H3. Additionally, positive updates were shared regarding four of their programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company received IND approval from the US FDA for Betabart (RV-01).
  • Positive clinical updates were provided across four programs.

Full Press Release Details

• Updates
• PDF
• September 6, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• November 16, 2023
• Announcements
• January 24, 2024
• Announcements
• December 15, 2023
• Announcements
• October 20, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What clinical study has Radiopharm Theranostics initiated?

Radiopharm Theranostics has initiated a Phase 1/2a clinical study for BetaBart (RV-01).

What approval did Radiopharm receive from the FDA?

Radiopharm Theranostics received IND approval from the US FDA for their therapeutic study targeting B7H3.

How many programs received positive updates?

Radiopharm provided positive updates across four of their clinical programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA IND approval clinical updates
Last updated: Sep 6, 2024